Abstract
Prolactin has been proposed as a potent coactivator of platelet aggregation, possibly contributing to thromboembolic events. The objective of the study was to evaluate the relationship between prolactinoma and deep vein thrombosis (DVT), pulmonary embolism (PE), and cerebrovascular accident (CVA). Subjects were identified from a prospectively maintained pituitary database at the Cleveland Clinic. We retrospectively reviewed the charts of 544 subjects: 347 patients with prolactinomas (prolactinoma group) and 197 patients with nonfunctional pituitary adenomas (control group). Main outcome measures were DVT, PE and CVA. We found that 19 (5.5 %) patients in the prolactinoma group and five (2.5 %) patients in the control group had documented DVT, PE, or CVA, but this difference was not significant (p = 0.109). However, the mean initial prolactin level was higher at the time of diagnosis among prolactinoma patients than among controls (815.23 ng/ml vs. 15.90 ng/ml; p < 0.001). Among prolactinoma patients, 15 (5.5 %) of 275 patients who underwent medical treatment (with cabergoline, bromocriptine, pergolide and/or other drug) and 4 (5.6 %) of 72 patients who underwent transsphenoidal surgery had documented DVT, PE, or CVA, which suggests that dopaminergic therapy did not influence the risk of thromboembolic events. Hyperprolactinemia per se does not appear to predispose to a hypercoagulable state.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Erem C, Kocak M, Nuhoglu I, Yilmaz M, Ucuncu O (2010) Blood coagulation, fibrinolysis and lipid profile in patients with prolactinoma. Clin Endocrinol (Oxf) 73(4):502–507
Prabhakar VK, Davis JR (2008) Hyperprolactinaemia. Best Pract Res Clin Obstet Gynaecol 22(2):341–353
Aron DC, Findling JW, Tyrrell JB (2007) Hypothalamus and pituitary gland, vol 8. The McGraw-Hill Companies, New York, pp 101–170
Melmed S, Casanueva FF, Hoffman AR et al (2011) Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96(2):273–288
Anaforoglu I, Ertorer ME, Kozanoglu I et al (2010) Macroprolactinemia, like hyperprolactinemia, may promote platelet activation. Endocrine 37(2):294–300
Wallaschofski H, Kobsar A, Sokolova O, Eigenthaler M, Lohmann T (2004) Co-activation of platelets by prolactin or leptin–pathophysiological findings and clinical implications. Horm Metab Res 36(1):1–6
Wallaschofski H, Donne M, Eigenthaler M et al (2001) PRL as a novel potent cofactor for platelet aggregation. J Clin Endocrinol Metab 86(12):5912–5919
Greer JP, Foerster J, Rodgers GM et al (2012) Wintrobe’s clinical hematology, 12th edn, pp 1466–1467
Heida NM, Schafer K, Konstantinides S (2009) Prolactin as a modulator of platelet function and thrombosis: the end of the story, or a new beginning? Thromb Haemost 101(6):991–992
Reuwer AQ, Nieuwland R, Fernandez I et al (2009) Prolactin does not affect human platelet aggregation or secretion. Thromb Haemost 101(6):1119–1127
Wallaschofski H, Lohmann T, Hild E et al (2006) Enhanced platelet activation by prolactin in patients with ischemic stroke. Thromb Haemost 96(1):38–44
Raaz D, Wallaschofski H, Stumpf C et al (2006) Increased prolactin in acute coronary syndromes as putative co-activator of ADP-stimulated P-selectin expression. Horm Metab Res 38(11):767–772
Wallaschofski H, Eigenthaler M, Kiefer M et al (2003) Hyperprolactinemia in patients on antipsychotic drugs causes ADP-stimulated platelet activation that might explain the increased risk for venous thromboembolism: pilot study. J Clin Psychopharmacol 23(5):479–483
Greenspan FS, Gardner DG (2012) Basic and clinical endocrinology, 7th edn. pp 118–137
Van Zaane B, Squizzato A, Reuwer AQ, van Zanten AP, Twickler MT, Dekkers OM, Cannegieter SC, Buller HR, Gerdes VE, Brandjes DP (2011) Arterioscler Thromb Vasc Biol 31(3):672–677
Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, Wass JAH (2011) JCEM 96(2):273
Karavitaki N, Thanabalasingham G, Shore HC, Trifanescu R, Ansorge O, Meston N, Tuner HE, Wass JA (2006) Do the limits of serum prolactin in disconnection hyperprolactinaemia need re-definition? A study of 226 patients with histologically verified non-functioning pituitary macroadenoma. Clin Endocrinol (Oxf) 65:524–529
Serri O, Li L, Mamputu J, Beauchamp MC, Maingrette F, Renier G (2006) Clinical Endocrinol 64:366–370
Schernthaner G, Prager R, Punzengruber C, Luger A (1985) Severe hyperprolactinemia is associated with decreased insulin binding in vitro and insulin resisitance in vivo. Diabetologia 28:138–142
Greenman Y, Tordjman K, Stern N (1998) Increased body weight associated with prolactin-secreting pituitary adenomas: weight loss with normalization of prolactin levels. Clin Endocrinol 48:547–553
Conflict of interest
The authors declare that there is no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mon, S.Y., Alkabbani, A., Hamrahian, A. et al. Risk of thromboembolic events in patients with prolactinomas compared with patients with nonfunctional pituitary adenomas. Pituitary 16, 523–527 (2013). https://doi.org/10.1007/s11102-012-0450-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11102-012-0450-4